Pursuit of a Valley fever vaccine passes significant milestone (2024)

Since settling in Arizona in 1978, Dr. John Galgiani has treated thousands of patients with Valley fever, some of whom left an indelible impression on his heart and soul.

"There was one patient in particular who had a genetic problem that led to a terrible, terrible outcome and the loss of that person to their family. And we couldn't help her," Galgiani remembered.

Image

Pursuit of a Valley fever vaccine passes significant milestone (1)

That woman and all of Galgiani's patients – past, present and future – fuel his passion for fighting Valley fever with awareness, education and, most of all, science.

"Why some people get sick and others don't is a fascinating question," said Galgiani, a professor in the Department of Medicine's Division of Infectious Diseases at the University of Arizona College of Medicine – Tucson and director of the Valley Fever Center for Excellence, which he founded in 1996. "The other really exciting idea is that we might be able to prevent this disease with a vaccine."

Researchers just took a giant step forward in making that idea a reality, as new National Institutes of Health funding is advancing a human vaccine candidate for Valley fever, formally known as coccidioidomycosis or cocci.

The significant milestone builds on the successful testing of a canine vaccine candidate for Valley fever that is under review by the U.S. Department of Agriculture's Center for Veterinary Biologics. If approved, it would be the world's first vaccine against a fungal infection.

Protection at both ends of the leash

In 2021, a U of A College of Medicine – Tucson-led study showed that two doses of a vaccine candidate provided dogs with a high level of protection against Coccidioides posadasii, a fungus that causes Valley fever. The study was a collaboration between the University of Arizona, Colorado State University and Anivive Life Sciences, a U of A startup that exclusively licensed the technology through Tech Launch Arizona, the university office that commercializes U of A innovations.

Image

Pursuit of a Valley fever vaccine passes significant milestone (2)

Anivive was recently awarded a contract by the National Institute of Allergy and Infectious Diseases, a division of the NIH, with first-year funding of $4.8 million and additional funding of up to $33 million to adapt the canine vaccine candidate for humans. The funding, some of which will be earmarked for the University of Arizona, will assist with the research, including the manufacturing, formulation, safety testing and support for a Phase 1 human clinical trial.

"There is really no reason, based on the biology, that the canine vaccine candidate couldn't also be developed to protect humans, and that is a very exciting possibility," said Galgiani, who is a member of the university's BIO5 Institute and sees patients through Banner Health's Valley Fever Center at Banner – University Medical Center in Phoenix and Tucson.

A viable vaccine, canine or human, would fill an immense need in the Southwest. An estimated $60 million per year is spent treating Valley fever in dogs, which are significantly more susceptible to the disease than humans, said Edward Robb, chief strategy officer for Anivive Lifesciences.

Indeed, it was Arizona dog owners who provided the initial grassroots funding that advanced the research to develop the canine vaccine candidate. Significant philanthropic support from a wide variety of donors has continued to advance the work.

The economic impact of Valley fever in humans far exceeds that of dogs. A 2021 U of A Health Sciences study estimated total lifetime costs at $736 million for the 10,359 Valley fever patients diagnosed in Arizona in 2019. Researchers found that disseminated Valley fever, in which the disease spreads to other parts of the body, resulted in the highest economic burden, at nearly $1.4 million per person.

"Two-thirds of all U.S. infections occur in our state. Surprisingly, many times patients who should be tested for Valley fever are not," Galgiani said. "There are more than 25 million people at risk of contracting Valley fever, and we do not yet have a vaccine to prevent it. The impact on this population is similar to that of polio before we had a vaccine. It's just that polio was a worldwide problem, whereas Valley fever risk exists in a relatively small geographic area."

Demystifying the desert's disease

Southern Arizona's low rainfall, high summer temperatures and moderate winter temperatures present the perfect environment for Coccidioides fungal spores to thrive in the soil. When the soil is disrupted by wind, earthquakes or activities such as construction, gardening or bicycling, the spores can become airborne, causing Valley fever when inhaled. Endemic areas include the southwestern U.S. (central California, Southern Arizona, New Mexico and western Texas), northern Mexico, and parts of Central and South America, though that is expanding. Coccidioides recently have been identified in parts of Utah and Washington. Based upon climate change forecasts, the Valley fever fungus may spread as far north as the Canadian border by the end of this century.

For people who have never had Valley fever, the chance of infection is about 3% per year, and the risk is cumulative. Cases have been seen in states across the U.S., as many visitors from non-endemic areas, where physicians may not be familiar with the disease, develop Valley fever after returning home from the Southwest.

Symptoms of Valley fever include fatigue, cough, chest pain, fever, rash, headache, joint aches and night sweats. About 5% of patients develop residual lung nodules and another 5% develop lung cavities that may rupture, causing chest pain and difficulty breathing. Approximately 1% to 2% of cases become disseminated and spread to the skin, bones or joints. Coccidioidal meningitis is the most severe complication, which, if untreated, is lethal.

Through the years, experts at the Valley Fever Center for Excellence have made significant contributions to the overall knowledge base about Valley fever, including research that led to the anti-fungal drug fluconazole becoming an approved treatment for Valley fever. Because Banner Health is the University of Arizona's clinical partner, Valley Fever Center physicians affiliated with Banner in Tucson and Phoenix have helped get patients with Valley fever diagnosed sooner.

Image

Pursuit of a Valley fever vaccine passes significant milestone (3)

Without the physician-scientists, veterinarians and researchers at the University of Arizona, the current vaccine candidates would not exist.

Marc Orbach, a plant sciences professor at the College of Agriculture, Life and Environmental Sciences, discovered that Coccidioides and Cochliobolus, a corn fungus, share a common gene, CPS1. Removing CPS1 from the corn fungus made it less harmful. Doing the same to Coccidioides made it completely harmless in rodent models, and when used as a vaccine it proved to be very protective against subsequent otherwise-lethal Valley fever infection. These discoveries were made along with Dr. Lisa Shubitz, a Valley Fever Center researcher and veterinarian.

The intellectual property and innovations from that research found a home with Anivive thanks to Tech Launch Arizona, the university's commercialization arm that connects faculty, researchers, staff and students with technology and business communities. Tech Launch Arizona creates commercial pathways to the marketplace, where Arizona inventions can create lasting social and economic impact.

As for Galgiani, his contributions cannot be overstated. The discoveries made by the collaboration of Orbach and Shubitz only occurred because there was a Valley Fever Center for Excellence that brought them together.

In addition to research and patient care, Galgiani helps inform national policy by working with state and national legislators and groups such as the Congressional Valley Fever Task Force and the National Academies. For his career's work, he was presented with the Arizona Bioindustry Association's Pioneer Lifetime Achievement Award last year and the U of A's inaugural Distinguished Director's Award in 2022. The latter award recognizes outstanding performances of department heads or directors whose vision, courage, standards and effectiveness have been transformative.

"There is growing concern about Valley fever, both as a significant public health problem today and the possibility that it might expand considerably in the future due to the effects of climate change. California has added Valley fever as one of the human health metrics that it tracks regarding the impact of climate change," Galgiani said. "The greater awareness emerging now about this disease is what the Valley Fever Center for Excellence has been advocating for more than a quarter century.

"The support of the NIH to progress the vaccine to humans is the peak of my career of more than 40 years as a researcher, physician and advocate dedicated to Valley fever awareness and solutions."

A version of this article originally appeared on the U of A Health Sciences website.

Pursuit of a Valley fever vaccine passes significant milestone (2024)

FAQs

How to avoid Valley fever in Arizona? ›

Prevention
  1. Wear a mask.
  2. Avoid very dusty areas, such as construction sites.
  3. Stay inside during dust storms.
  4. Wet the soil before digging in it, or avoiding soil if you're at higher risk of infection.
  5. Keep doors and windows tightly closed.
  6. Clean skin injuries with soap and water.

Is there a vaccine for Valley fever in humans? ›

Rift Valley Fever Vaccines

An inactivated vaccine has been developed for human use, but it is not licensed and or commercially available. It has been used experimentally to protect veterinary and laboratory personnel at high risk of exposure to RVF. Other candidate vaccines are under investigation.

What state has the most Valley fever cases? ›

States usually report a total of 10,000 - 20,000 cases of Valley fever yearly in the United States. Most cases occur in California and Arizona among people over 60 years.

How can coccidioidomycosis Valley fever be prevented? ›

Avoid excavation and dust-producing activities (e.g., driving, grading, plowing, drilling, blasting) or minimize soil disturbance when possible. Adopt engineering and work practice controls that reduce exposure to airborne dust: Use water or other material to stabilize soil. Use tarps to stabilize soil waste piles.

Is Valley fever bad for you? ›

Most people fully recover from Valley fever. In rare cases, Valley fever can spread to other parts of the body and infect the brain, joints, bone, skin, or other organs. This form of Valley fever can be very serious and fatal.

Can Valley fever go away on its own? ›

Most people don't get sick. And when valley fever symptoms do appear, they usually go away on their own. If not, there are medicines that can typically clear them up. But in rare cases, the fungus spreads to other parts of the body.

Who is the most common victim of Valley fever? ›

Valley Fever is most common in adults aged 60 and older but can affect people of any age.

What is the new treatment for Valley fever? ›

Three newer medications — voriconazole (Vfend), posaconazole (Noxafil) isavuconazonium sulfate (Cresemba) — may also be used to treat more-serious infections. For many people, a single bout of valley fever results in lifelong immunity.

What does Valley fever rash look like? ›

What is Valley fever skin rash like? Valley fever can cause rashes that look several different ways. A common presentation is as painful or tender, slightly elevated red nodules or bumps, which may change color to bluish to brown and often occur on the legs, but may occur on the chest, arms and back.

What is another name for Valley fever? ›

Valley fever (also called coccidioidomycosis or “cocci”) is a disease caused by a fungus that grows in the soil and dirt in some areas of California and the southwestern United States.

What is the new test for Valley fever? ›

Coccidioides precipitin is a blood test that looks for infections due to a fungus called Coccidioides, which causes the disease coccidioidomycosis or valley fever. Blood is drawn from a vein (venipuncture), usually from the inside of the elbow or the back of the hand.

What is the survival rate for Valley fever? ›

In most cases, people with Valley fever infections recover without any long-term effects. A small number of people develop ongoing lung infections that may take several years to resolve. Less than 1% of people diagnosed with Valley fever die from it.

Can Valley fever lay dormant in your body? ›

Answer: In many cases the fungus does remain in the body. If the person's immune system is greatly immunocompromised, a reactivation of the disease may occur. This has been found to occur in many patients with AIDS and disseminated Valley fever.

What is the Valley fever lawsuit? ›

SAN FRANCISCO (CN) – Dozens of California inmates who said they were subjected to cruel and unusual punishment after contracting a potentially deadly disease while imprisoned in Central Valley facilities saw their lawsuits tossed by the Ninth Circuit on Friday.

How do people get cocci bacteria? ›

Coccidioidomycosis (Valley Fever)

Coccidioidomycosis, also known as Valley fever, is an infection caused by breathing in the spores of the fungus Coccidioides found in the soil in the southwestern United States and California, northern Mexico and parts of Central and South America.

What time of year is Valley fever in Arizona? ›

In Arizona, the peak seasons occur from June through August and from October through November. In California, the summer months of June through August have the most cases reported. What is the incubation period for Valley fever? Symptoms usually develop within 7-28 days after exposure.

How common is Valley fever in dogs in Arizona? ›

Approximately 6-10% of dogs living in Pima, Pinal, and Maricopa counties in Arizona will become sick with Valley Fever each year. The rate of illness in other Valley Fever endemic locations is not known, but it is lower most places than central and southern Arizona. Not all dogs who breathe in spores become sick.

Is there a way to prevent Valley fever in dogs? ›

If you live in a region where valley fever is a risk, you should keep your dog indoors more than outdoors. Prevent your dog from digging when they are outside, and try to stay away from areas where the soil is loose and dusty, such as construction sites or spaces with limited ground-cover plants.

Who is more at risk for catching Valley fever? ›

Risk Factors for Infection

Anyone who lives in, visits, or travels through the areas where the fungus grows in the soil (these areas are called endemic) may acquire Valley Fever. There is no evidence indicating any particular group of people is more or less likely to acquire Valley Fever.

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Domingo Moore

Last Updated:

Views: 5291

Rating: 4.2 / 5 (73 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Domingo Moore

Birthday: 1997-05-20

Address: 6485 Kohler Route, Antonioton, VT 77375-0299

Phone: +3213869077934

Job: Sales Analyst

Hobby: Kayaking, Roller skating, Cabaret, Rugby, Homebrewing, Creative writing, amateur radio

Introduction: My name is Domingo Moore, I am a attractive, gorgeous, funny, jolly, spotless, nice, fantastic person who loves writing and wants to share my knowledge and understanding with you.